[37]
Alberts, B.; Johnson, A.; Lewis, J.; Raff, M.; Roberts, K.; Walter, P. The Adaptive Immune System.Molecular Biology of the Cell, 4th ed; Garland Science: New York, NY, USA, 2002.
[43]
Payes, C.J. DanielsWells, T.R.; Maffía, P.C.; Penichet, M.L.; Morrison, S.L.; Helguera, G. Genetic engineering of antibody molecules. Rev Cell Biol Mol Med, 2015, 1(3), 1-52.
[142]
Coleman, R.L.; Lorusso, D.; Gennigens, C.; González-Martín, A.; Randall, L.; Cibula, D.; Lund, B.; Woelber, L.; Pignata, S.; Forget, F.; Redondo, A.; Vindeløv, S.D.; Chen, M.; Harris, J.R.; Smith, M.; Nicacio, L.V.; Teng, M.S.L.; Laenen, A.; Rangwala, R.; Manso, L.; Mirza, M.; Monk, B.J.; Vergote, I.; Raspagliesi, F.; Melichar, B.; Gaba Garcia, L.; Jackson, A.; Henry, S.; Kral, Z.; Harter, P.; De Giorgi, U.; Bjurberg, M.; Gold, M.; O’Malley, D.; Honhon, B.; Vulsteke, C.; De Cuypere, E.; Denys, H.; Baurain, J-F.; Zamagni, C.; Tenney, M.; Gordinier, M.; Bradley, W.; Schlumbrecht, M.; Spirtos, N.; Concin, N.; Mahner, S.; Scambia, G.; Leath, C.; Farias-Eisner, R.; Cohen, J.; Muller, C.; Bhatia, S. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol., 2021,
22(5), 609-619.
[
http://dx.doi.org/10.1016/S1470-2045(21)00056-5] [PMID:
33845034]
[149]
Ameratunga, M.; Harvey, R.D.; Mau-Sørensen, M.; Thistlethwaite, F.; Forssmann, U.; Gupta, M.; Johannsdottir, H.; Ramirez-Andersen, T.; Bohlbro, M.L.; Losic, N.; Ervin-Haynes, A.L.; Lopez, J.S.; Vergote, I. First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors. J. Clin. Oncol., 2019, 37(15), 2525-2525.
[155]
Petrylak, D.P.; Heath, E.I.; Sonpavde, G.; George, S.; Morgans, A.K.; Eigl, B.J.; Picus, J.; Cheng, S.Y.; Hotte, S.J.; Gartner, E.M.; Vincent, M.; Chu, R.; Anand, B.; Morrison, K.; Jackson, L.; Reyno, L.M.; Yu, E.Y. Anti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC). Genitourinary (nonprostate) cancer Meeting Abstract | 2016 ASCO Annual Meeting I. 2016.
[171]
Chang, C.; Frey, G.; Boyle, W.J.; Sharp, L.L.; Short, J.M. Novel conditionally active biologic anti-Axl antibody-drug conjugate demonstrates anti-tumor efficacy and improved safety profile. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research. Cancer Res., 2016, 76(14)(Suppl.)
[172]
Sharp, L.L.; Chang, C.; Frey, G.; Wang, J.; Liu, H.; Xing, C.; Yalcin, S.; Walls, M.; Ben, Y.; Boyle, W.J.; Short, J.M. Anti-tumor efficacy of BA3021, a novel Conditionally Active Biologic (CAB) anti-ROR2 ADC. In: Proceedings of the American Association for Cancer Research Annual Meeting, 2018, 78(13 Suppl)
Download PDF Flyer